NGAL

The assays measure biomarkers — NGAL and KIM-1 — that the company said will help drug developers gauge the right dose for drugs in Phase I trials, validate proof-of-concept in Phase II, and confirm efficacy and safety in Phase III studies by helping avoid kidney damage in participants.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.